🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

💥 Great talk by Giulio Francolini convincing that the best strategy for high-risk PCa is to integrate systemic treatment with local Tx-intensification. One does not exclude the other‼️ #ESTRO2025

🚀 oustanding presentation by Vedang Murthy showing that #AUGMENTED RT ⬆️ outcomes with extremely limited tox in high-risk PCa #ESTRO2025

🎬 coming soon…a number of trials on the way to intensify RT+ADT with ARPI in high-risk PCa 🔎 insightful presentation by silke gillessen #ESTRO25

🔎interesting data presented by Fabio Matrone suggesting that a plasma proteomics signature in oligorecurrent HSPC pts undergoing SBRT could be used as prognostic indicator for biochemical progression- and disease progression-free survival #ESTRO2025

💥 🇮🇹#DART PHASER trial shows that CT-based adaptive moderate hypofx-RT might be beneficial in PCa postop setting 👏🏻 Luca Nicosia MD #ESTRO25

🚀 Impressive data from 🇧🇪 trial showing that SBRT can delay ADT in PSMA PET-staged oligorecurrent HSPC PCa, with over 2/3 of patients remaining ADT-free at 2-yrs❗️ #ESTRO2025

🔎 Analysis of the 🇬🇧 PACE-B trial indicates that baseline urinary symptoms correlate with late GU tox, thus informing treatment selection. 👉🏻 Baseline IPSS of 11 is the optimal cut-off #ESTRO2025

💥 Reassuring data from the 🇨🇦 randomized HOPE trial that hypo-fx WPRT (25/5) post-HDR boost is as well tolerated as conventionally-fractionated WPRT (45/25) after 12 months of follow-up #ESTRO2025

🔎 🇩🇪phase 2 trial shows that PSMA-PET-guided target volume delineation resulted in significant changes in 29 out of 139 patients (20.9%) 👉🏻 Ga-PSMA-11 PET/CT mandatory for treatment-naïve patients with high-risk PCa❗️ #ESTRO2025

🎬 long-term results from the 🇩🇪 SAKK 0910 phase III trial shows that salvage dose-escalated RT (70Gy) is associated with ⬇️ QOL in the urinary symptom scale #ESTRO2025

💥 Great talk by Neil Desai showing that MR/spacer-facilitated neurovascular sparing SAbR mitigates QoL impacts of PCa RT at early timepoints (3-months) #POTEN-C trial 🇺🇸 #ESTRO2025

🆒 making friends, having fun…and giving rise to an international dream team 🚀 #ESTRO2025 🙏 to Constantinos Zamboglou🇨🇾, Jennifer Le Guévelou🇫🇷, Cédric Draulans🇧🇪, Simon Spohn🇩🇪, Binnaz Yasar🇬🇧, Astrid Carsson🇸🇪, Casper Reijnen🇳🇱, Denis Panizza🇮🇹, 💖😍duygu💖🇮🇹

🔎Excellent review on SBRT for primary kidney tumors showing that: ✅ achieves LC rates of 95-100%, with low rates of Grade 3 tox ✅ can allow preservation of ipsilateral renal function and ✅ can be a viable treatment option in patients with a solitary kidney #ESTRO2025

🚀 🔝critical review by Giulia Marvaso on the role of SBRT for kidney cancers compared to other histologies: 👉🏻 “a paradox of growing enthusiam with limited (randomized) data” #ESTRO2025

🎯 major takeaways from the brilliant presentation on bladder sparing treatment by Robert Huddart💙 #ESTRO2025

🔎 interesting presentation by Valérie Fonteyne on adj RT in MBIC: 📌 can be considered for patients at high risk of locoregional recurrence 📌 challenges in the optimal timing and combination with adjuvant chemo and/or immunotherapy #ESTRO2025

🔎 provocative talk by Roberto Iacovelli that bladder sparing strategy in MIBC with medical therapy alone is feasible! 🚦definition of cCR with multimodal strategies such as TUR, mpMRI and the ctDNA is the major challenge❗️ #ESTRO2025

🎩🎩 off to 🇮🇹 Giulio Francolini Giulia Marvaso and Ciro Franzese for handling the GU sessions #ESTRO25 so well, either as chairs or speakers ⚡️so inspiring for the younger colleagues 🤩 #ProstateCancer #radonc ESTRO

Hard work pays off!👏🏻

💥Our scoping review on toxicity factors in breast RT is out! Great work by Riccardo Ray Colciago! 👏🏼 From patient traits to treatment techniques ~ what really drives toxicity? 🚗 📝 Read it here: mdpi.com/2673-6411/5/2/… #RadOnc #BreastCancer Stefano Arcangeli Chiara Chissotti Matteo Mombelli